Sharon Bio-Medicine considers restructuring $16.5 million convertibles

By Toni Weeks

San Luis Obispo, Calif., Nov. 25 - Sharon Bio-Medicine Ltd. informed the Bombay Stock Exchange that it will hold a board of directors meeting on Nov. 26 to consider the restructuring of the company's $16.5 million of outstanding foreign-currency convertible bonds and the issue of new bonds in lieu of accrued interest of the bonds.

Sharon Bio-Medicine is a Mumbai, India-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.